Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing
Li J, Arsang-Jang S, Cheng Y, Sun F, D’Souza A, Dhakal B, Hari P, Huang Q, Auer P, Li Y, Urrutia R, Zhan F, Shaughnessy J, Janz S, Dong J, Cheng C. Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing. Blood Cancer Journal 2024, 14: 38. PMID: 38443358, PMCID: PMC10915134, DOI: 10.1038/s41408-024-01024-8.Peer-Reviewed Original ResearchMeSH KeywordsHumansMultiple MyelomaParaproteinemiasPlasma CellsPrognosisSequence Analysis, RNATumor MicroenvironmentConceptsInternational Staging SystemPlasma cell malignancyMultiple myelomaCell malignancySpectrum of plasma cell dyscrasiasPlasma cell gene signaturePresence of cytogenetic abnormalitiesRevised ISSHeterogeneous plasma cell malignancyTumor immune microenvironmentPlasma cell dyscrasiaRefining risk stratificationPlasma cell signatureTherapeutic approach to MMShorter overall survivalCytogenetic abnormalitiesOverall survivalR-ISSTP53 mutationsImmune microenvironmentPrognostic effectClinical outcomesStaging systemRisk stratificationPrognostic powerAssessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy
Han J, Dong Y, Zhu X, Reuben A, Zhang J, Xu J, Bai H, Duan J, Wan R, Zhao J, Bai J, Xia X, Yi X, Cheng C, Wang J, Wang Z. Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy. Nature Communications 2024, 15: 1199. PMID: 38331912, PMCID: PMC10853168, DOI: 10.1038/s41467-024-45361-5.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, NeoplasmHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHLA AntigensHumansImmunotherapyNeoplasmsTumor MicroenvironmentConceptsImmune checkpoint inhibitorsHLA-INeoantigen presentationPresentation capacityPatients treated with immune checkpoint inhibitorsHuman leukocyte antigen class IICI responseImmune checkpoint inhibitor treatmentResponse to immunotherapyAntigen presentation capacityAntigen presentation pathwayCheckpoint inhibitorsSurvival benefitNeoantigen productionTumor microenvironmentCancer patientsPresentation pathwayClinical utilityClass IPatientsTumorPresentationPresentation scoreScoresImmunotherapy